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2:05 pm Vital Signs Overview Coleen A. Boyle, PhD, MSHyg
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5Image of Vital Signs
6Population
4,816
Pregnancies reported from 
U.S. territories 
4,199
Live born infants by 
February 1, 2018
2,141
Children 1 year by 
February 1, 2018
1,450
Children 1 year by February 1, 
2018, with some follow-up 
care reported
7Reported Clinical Care
8CDC Clinical Guidance
• CDC released clinical guidance on the evaluation and management of 
infants with possible congenital Zika virus infection in January 2016. 
– Standard evaluation at birth and well-child visit:
• Physical exam
• Newborn hearing screen
• Developmental monitoring and screening
• Vision screening
– Head ultrasound and comprehensive ophthalmologic exam 
performed by age 1 month
Staples JE 2016; Adebanjo T, 2017
Karoly LA, 2005; Yoshinaga-Itano C, 2017; Sonsken PM, 1991; Ventura LO, 2017; Bright Futures Steering Committee, 2006
9Recommended Screening: Physical Examination  
95% 
of the 1,450 infants included 
in the analysis had the 
recommended physical 
exam reported to the 
USZPIR. 
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Recommended Screening: ABR-Based Hearing 
Screening or Evaluation 
48% 
of the 1,450 infants included 
in the analysis had the 
recommended ABR-based 
hearing screening or 
evaluation reported to the 
USZPIR. 
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Recommended Screening: Developmental Screening 
or Evaluation 
76% 
of the 1,450 infants included 
in the analysis had the 
recommended 
developmental screening or 
evaluation reported to the 
USZPIR. 
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Recommended Screening: Neuroimaging
60% 
of the 1,450 infants included 
in the analysis had the 
recommended 
neuroimaging reported to 
the USZPIR. 
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Recommended Screening: Ophthalmologic Exam by an 
Ophthalmologist  
36% 
of the 1,450 infants included 
in the analysis had the 
recommended 
ophthalmologic exam by an 
ophthalmologist reported to 
the USZPIR. 
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Adverse Infant Outcomes Assessed
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Zika-associated birth defects
• Microcephaly at birth
Birth head circumference ˂3rd percentile for infant sex and gestational 
age based on INTERGROWTH-21st online percentile calculator
• Selected congenital brain anomalies*
Intracranial calcifications; cerebral atrophy; abnormal cortical formation 
(e.g., polymicrogyria, lissencephaly, pachygyria, schizencephaly, gray 
matter heterotopia); corpus callosum abnormalities; cerebellar 
abnormalities; porencephaly; hydranencephaly; 
ventriculomegaly/hydrocephaly
• Selected congenital eye anomalies
Chorioretinal anomalies involving the macula (e.g., chorioretinal atrophy 
and scarring, macular pallor, and gross pigmentary mottling),excluding 
retinopathy of prematurity; microphthalmia or anophthalmia; 
coloboma; cataract; intraocular calcifications; optic nerve atrophy, 
pallor, and other optic nerve abnormalities.
*Neural tube defects removed from original case definition
Subcortical 
calcifications  
Skull collapse
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Neurodevelopmental abnormalities possibly 
associated with Zika
• Hearing abnormalities
• Congenital contractures
• Seizures
• Body tone abnormalities
• Movement abnormalities
• Swallowing abnormalities
• Possible developmental delay based on 
standardized screening or evaluation
• Possible visual impairment
• Postnatal-onset microcephaly Congenital contractures 
with knee dislocation
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Zika-related health outcomes 
Outcomes reported among children aged ≥1
From pregnancies with any 
laboratory evidence of 
possible Zika virus infection 
(N = 1,450)
Zika-associated birth defect 87 (6%)
Neurodevelopmental abnormality possibly associated with 
congenital Zika virus infection 136 (9%)
Zika-associated birth defect and neurodevelopmental abnormality 
possibly associated with congenital Zika virus infection 20 (1%)
Total with Zika-associated birth defect and/or 
neurodevelopmental abnormality possibly associated with 
congenital Zika virus infection
203 (14%)
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Outcomes among children aged ≥1
From pregnancies
with any laboratory 
evidence of possible 
Zika virus infection 
(N = 1,450)
From pregnancies
with RNA-positive 
Zika virus infection 
(N = 943)
Zika-associated birth defect 87 (6%) 62 (7%)
Neurodevelopmental abnormality possibly associated with 
congenital Zika virus infection 136 (9%) 99 (10%)
Zika-associated birth defect and neurodevelopmental 
abnormality possibly associated with congenital Zika virus 
infection
20 (1%) 17 (2%)
Total with Zika-associated birth defect and/or 
neurodevelopmental abnormality possibly associated with 
congenital Zika virus infection
203 (14%) 144 (15%)
Zika-related health outcomes from RNA-positive pregnancies 
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Comparison with baseline prevalence
• Zika-associated birth defects (brain and eye 
only) among liveborn infants before Zika = 
0.16%
• 6% with Zika-associated birth defects in this 
report is about a 30-fold increase over 
the baseline 
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All Zika-exposed children need evaluation
Among 1,386 children who did not have microcephaly at birth
• 822 (59%) were reported to have a neuroimaging exam
—14 (~2%) had at least one brain anomaly identified
• 494 (36%) were reported to have an ophthalmology exam
—12 (~2%) had at least one eye anomaly identified
Had these infants not received neuroimaging or 
ophthalmologic evaluation, 26 brain or eye anomalies 
in 23 children might have gone undetected 
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Limitations
• Data are limited to evaluations and clinical care received and reported to 
the USZPIR
• Appropriate estimates of baseline frequencies of neurodevelopmental 
abnormalities among very young children are not available
• Cannot attribute causality of these health problems to Zika virus infection 
during pregnancy
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Implications 
• Babies born to mothers with Zika during pregnancy 
should receive special follow-up care, even if they 
appear healthy
• According to what was reported, many babies did not 
receive all the recommended care
• Without evaluation, some health problems may not be 
detected or treated
• Identifying health problems early can help babies and 
children get the care they need
Monitoring and evaluation of children with congenital Zika virus exposure is 
essential to ensure early detection of and early referral to intervention services that 
might improve outcomes
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What can health departments do?
• Work with healthcare providers to collect and report medical 
information about babies in the US Zika Pregnancy and Infant Registry 
through at least two years of age  
• Share CDC clinical guidance for mothers and babies affected by Zika, 
and CDC’s resources for checking development
• Keep raising awareness about the risks of Zika during pregnancy and 
how people can protect themselves 
• Connect affected families with support groups and services 
• Encourage communication between healthcare providers and families 
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Resources 
Vital Signs 
Website
www.cdc.gov/vitalsigns/Zika-
territories 
Infant Follow-Up 
Resources
https://www.cdc.gov/pregnan
cy/zika/clinician-resources-
infants.html 
CDC Infant 
Guidance
https://www.cdc.gov/pregnan
cy/zika/testing-follow-
up/infants-children.html 
Vital Signs 
MMWR Report
https://www.cdc.gov/mmwr/
volumes/67/wr/mm6731e1.h
tm?s_cid=mm6731e1_w  
Zika and 
Pregnancy 
Information
https://www.cdc.gov/pregnan
cy/zika/index.html 
Informational 
Fact Sheets and 
Videos
https://www.cdc.gov/pregnan
cy/zika/materials/index.html
General Zika 
Information
www.cdc.gov/zika
Infant Guidance 
Medscape Video
https://www.medscape.com/
viewarticle/899123?src=par_c
dc_stm_mscpedt&faf=1 
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For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
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CDC RECOMMENDATIONS: 
OPHTHALMOLOGIC SCREENING
27
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Who should be referred for screening and when?
By 1 month of age:
– All infants with abnormalities 
consistent with congenital Zika
syndrome (and whose mothers had 
possible Zika virus exposure during 
pregnancy, regardless of maternal 
testing results), AND
– All infants of mothers with laboratory 
evidence of Zika virus infection during 
pregnancy (including infants without 
abnormalities consistent with 
congenital Zika syndrome)
Adebanjo T, Godfred-Cato S, Viens L, et al. Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants 
with Possible Congenital Zika Virus Infection - United States, October 2017. MMWR Morb Mortal Wkly Rep. 2017 Oct 20;66:1089-
1099.
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Why do these infants all need to be examined 
by an Ophthalmologist?
• Ocular abnormalities have 
been identified in infants 
both with and without 
microcephaly
• Abnormalities have been 
found in the anterior and 
posterior ocular 
structures
Photo credit: National Eye Institute
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Ocular Anatomy
Photo credit: National Eye Institute 
Focal Point
Optic Nerve
Retina
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OCULAR FINDINGS 
ASSOCIATED WITH 
CONGENITAL ZIKA VIRUS 
INFECTION 
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Macular and Optic Nerve Findings
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• Commonly reported 
macular findings
• Macular mottling
• Chorioretinal atrophy
• Commonly reported optic 
nerve findings
• Hypoplasia
• Increased cup to disk ratio
• Pallor  
Macular mottling, chorioretinal
atrophy, and 
optic nerve hypoplasia
Ventura CV, et al. Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. Arq Bras
Oftalmol. 2016 Feb;79(1):1-3.
All Rights Reserved, Duke Medicine 2007
Other Ocular Findings 
Iris colobomas
• Congenital 
glaucoma
• Iris colobomas
• Microphthalmia
• Subluxation of the 
lens
• Cataract
• Intraocular 
calcification
• Strabismus
• Nystagmus 
Congenital Glaucoma
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Microphthalmia
• de Paula Freitas, et al. Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika Syndrome. Ophthalmology. 
2017 Dec;124(12):1876-1878. 
• Yepez JB, et al. Ophthalmic Manifestations of Congenital Zika Syndrome in Colombia and Venezuela. JAMA Ophthalmol. 2017 
May 1;135(5):440-445.
All Rights Reserved, Duke Medicine 2007
Visual Function
• Of children tested, 100% had visual 
impairment, while only 30-40% had any 
ocular abnormalities.
• Cortical visual impairment might be the 
most common cause of blindness among 
children with congenital Zika syndrome 
National Eye Institute
• Vercosa I, Carneiro P, Vercosa R, et al. The visual system in infants with microcephaly related to presumed congenital Zika
syndrome. J AAPOS. 2017;21:300-304. 
• Ventura LO, Ventura CV, Lawrence L, et al. Visual impairment in children with congenital Zika syndrome. J AAPOS 2017;21:295-
9. 
• Ventura LO, Ventura CV, Dias NC, et al. Visual impairment evaluation in 119 children with congenital Zika syndrome. J AAPOS. 
2018 Jun;22(3):218-222.
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What can be done for a child if an eye 
problem is identified?
• Timely Referral:
– Low vision specialist
– Early intervention
• Treatments:
– Glasses
American Printing House for the Blind.
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A missed opportunity
• In the US territories, only 
36% of infants had an eye 
exam by 1 y/o
• Timely referral is critical!
• Maximizing visual 
development can help an 
infant’s overall global 
development
Image from: 
https://she.blogs.latrobe.edu.au/2016/05/26/7-
tips-handle-exam/white-rabbit/. Last accessed 
7/23/18 
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Why is Ophthalmologic Screening Important?
• Healthy-appearing infants with 
congenital Zika virus infection 
may have ocular findings and/or 
visual impairment
• Cortical visual impairment might 
be the most common cause of 
blindness among children with 
congenital Zika syndrome 
• Timely referral to a low vision 
specialist and early intervention 
can help an infant’s overall 
global development
Image from: https://forlittleeyes.com/2010/10/22/your-
stories-jacks-journey-with-infant-cataracts/. Last 
accessed 7/23/18 
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Questions?
Grace.Prakalapakorn@duke.edu
S. Grace Prakalapakorn, MD, MPH
Associate Professor of Ophthalmology & Pediatrics
Duke University, School of Medicine
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Health Outcomes in Children with 
Congenital Zika Exposure
V. Fan Tait, MD, FAAP
Chief Medical Officer
American Academy of Pediatrics
Meg Fisher, MD, FAAP
Medical Director,
Unterberg Children’s Hospital at 
Monmouth Medical Center
Professor of Pediatrics,
Drexel University College of Medicine
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Mission: to attain optimal physical, mental, 
and social health and well-being for all
infants, children, adolescents and young adults.
41
AAP ZIKA ACTIVITIES
• Collaborations
• Articles linking to guidance
• Webinars
• Psychosocial support materials
• Periodic survey
• Project ECHO® Zika
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VITAL SIGNS:
RELEVANCE FOR PEDIATRICS
• Highlights importance of:
– Zika prevention, anticipatory guidance for families
– Developmental screening, ongoing monitoring
– Medical home
• Critical need for enhanced communication between 
obstetric providers, hospital/birthing facility, 
neonatologists, and pediatric care providers
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PEDIATRICIANS’ EXPERIENCES AND
CHALLENGES
• May need to take extra steps
• Access to information
• Babies born without abnormalities
• Migration of parents and children
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ONGOING CONCERNS
• Loss to follow-up
• Developmental screening
• Special populations at-risk
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OUTREACH TO PEDIATRICIANS
• Challenges exist; AAP can help
• Importance of enhancing coordination of care
• Clear communication
• Connection with AAP Chapters
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MOVING FORWARD
• Lessons from Zika can inform future response efforts 
• Registries/reporting
• EHR/EMR: links from mother’s to baby’s medical record
• Communications (obstetric providers to hospital/birthing 
facility/neonatologists to pediatrician)
• Impact of social/societal factors on child outcomes
• Keeping clinicians informed in a crisis
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ECHO SESSIONS AS A MODEL
• ECHO (Extension for Community Healthcare Outcomes)
• Model for telementoring
• Leverage technology to connect specialty care 
providers with primary care providers
• Facilitate connections, areas with limited pediatric care
• Didactic and case-based presentations
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WHAT WE STILL DON’T KNOW
• Long-term effects of congenital Zika virus 
infection
• Exact strategies to improve outcomes in 
infants who develop abnormalities later on
• Subtle clinical findings associated with 
congenital Zika virus infection
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RESOURCES
• AAP Zika Virus Resource Page (www.aap.org/zika)
• AAP Zika Key Information for Pediatricians 
(www.aap.org/zikakey) 
• AAP Project ECHO Zika (www.aap.org/en-us/professional-
resources/practice-transformation/echo/Pages/AAP-Project-
ECHO-Zika.aspx) 
• AAP Children and Disasters Web site (www.aap.org/disasters)
• AAP HealthyChildren.org Zika Virus Info for Parents 
(www.healthychildren.org/zikavirus)  
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CONTACT INFORMATION
V. Fan Tait, MD, FAAP
Phone: 630-626-6104
Email: FTait@aap.org
Contact the AAP Disaster Preparedness and Response Initiatives 
staff: DisasterReady@aap.org
Meg Fisher, MD, FAAP
Phone: 732-923-7250
Email: Margaret.Fisher@rwjbh.org
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CDC Vital Signs Electronic Media Resources
 Become a fan on Facebook
www.facebook.com/cdc
 Follow us on Twitter
www.twitter.com/CDCgov
 Syndicate Vital Signs on your website
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/305883 
 Vital Signs interactive buttons and banners
https://www.cdc.gov/socialmedia/tools/buttons/vitalsigns
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Thank You
Provide feedback on this teleconference: OSTLTSFeedback@cdc.gov
Please mark your calendars for the next 
Vital Signs Town Hall Teleconference
September 11, 2018
2:00–3:00 PM (EDT)
For more information, please contact Centers for Disease Control and Prevention.
1600 Clifton Rd, NE, Atlanta, GA 30333
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
Email: cdcinfo@cdc.gov
Web: www.cdc.gov
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control 
and Prevention.
